NCT05251467 (CARDS-CF) is a clinical trial of Focus group in Cystic Fibrosis, sponsored by Nottingham University Hospitals NHS Trust.

Who is sponsoring NCT05251467?

NCT05251467 is sponsored by Nottingham University Hospitals NHS Trust.

What drugs are being tested in NCT05251467?

Interventions in NCT05251467: Focus group, Patient interview (n = approximately 10), Questionnaire (n = 180), Testing of the pilot PROM in a smartphone app (n = 150).

What condition does NCT05251467 study?

NCT05251467 studies Cystic Fibrosis, Digestive System Disease, Genetic Disease, Respiratory Tract Diseases, Lung Diseases, Pancreatic Disease.

Is NCT05251467 still recruiting?

NCT05251467 is currently completed. Last updated 22 July 2024.

Last reviewed 2024-07-22 · How we verify

NCT05251467: CARDS-CF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF

Completed Last updated 22 July 2024

What this trial tests

trial testing Focus group in Cystic Fibrosis in 350 participants. Completed in 3 December 2023.

Timeline

28 February 2022

Primary endpoint
3 December 2023

3 December 2023

Quick facts

Lead sponsor	Nottingham University Hospitals NHS Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	350
Start date	28 February 2022
Primary completion	3 December 2023
Estimated completion	3 December 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Focus group
Patient interview (n = approximately 10)
Questionnaire (n = 180)
Testing of the pilot PROM in a smartphone app (n = 150)

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →
Digestive System Disease — all drugs for Digestive System Disease →
Genetic Disease — all drugs for Genetic Disease →
Respiratory Tract Diseases — all drugs for Respiratory Tract Diseases →

Sponsor

Nottingham University Hospitals NHS Trust

Who can join

12 and older, any sex, with Cystic Fibrosis or Digestive System Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
Calthorpe RJ, Goodchild N, Gleetus V, Premakumar V, et al · · 2023 · cited 9× · PMID 37881465 · DOI 10.3310/nihropenres.13384.2
CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.
Calthorpe RJ, Saumtally HA, Howells LM, Goodchild NJ, et al · · 2025 · PMID 40568613 · DOI 10.1016/j.mcpdig.2025.100203

Verify or expand the search:

Other trials of Focus group

Trials testing the same drug.

NCT07129265 — Understanding Vape Marketing Study · enrolling by invitation
NCT06562751 — Developing an Intervention to Help Nurses Improve Sexual Healthcare in Men With Inflammatory Bowel Disease · completed
NCT06535802 — iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed · recruiting
NCT05749406 — Parental Attitudes to Neoanus Dilatations Post-reconstruction in Anorectal Malformations · unknown
NCT05925088 — Exercise Videos - Perspectives of People Living With Chronic Pain · completed

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Nottingham University Hospitals NHS Trust trials

Trials by the same sponsor.

NCT07350408 — Mapping Post-falls Organisational Processes in Care Homes · recruiting
NCT07036081 — A Single Arm Intervention Study to Assess the Acceptability, Tolerance and Ease of Use of Wilbo's Blends+ (Commercial En · NA · completed
NCT07303569 — Prevention of Pressure Injury (PI) in Hospitalised Infants, Children, and Young People (CYP) (Aged 0-19 Years) · recruiting
NCT06572345 — Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study · NA · recruiting
NCT07136298 — Seizure Identification on the Intensive Care Unit (ICU) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05251467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nottingham University Hospitals NHS Trust
Last refreshed: 22 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05251467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing